DalsnaFinance › IPOs › Apimeds Pharmaceuticals US › IPO
Apimeds Pharmaceuticals US, Inc. completed its initial public offering on NYSE on May 9, 2025, pricing at $4.00 a share.
| Ticker | APUS |
|---|---|
| Exchange | NYSE |
| Status | Completed |
| Listing date | May 9, 2025 |
| Offering price | $4.00 |
| Shares offered | 3,375,000 |
| Total raised | $14M |
Apimeds Pharmaceuticals US, Inc. sold 3,375,000 shares at $4.00 each on NYSE. Multiplied out, that is $13.5 million in gross proceeds, the figure before underwriting discounts and offering expenses, and it agrees with the $14 million total recorded for the deal.
Measured by money raised, Apimeds Pharmaceuticals US, Inc. was tied for the 437th largest (level with 2 other deals) of 473 completed IPOs with a recorded deal size that this site tracks since October 5, 2024. The median deal in the same window raised $200 million.
Among the 126 listings on NYSE alone, it is tied for the 108th largest (level with 2 other listings).
May 2025 saw 34 completed IPOs in the site's data; by amount raised, Apimeds Pharmaceuticals US, Inc. was the 34th largest of the 34 deals with a recorded size.
Its $4.00 offer price was tied for the 440th highest (level with 37 other listings) of the 479 listings in the window with a recorded price. A share price on its own says nothing about a company's value; it depends on how many shares exist.
Apimeds Pharmaceuticals US, Inc. — quote, profile and latest news →
Source: SEC EDGAR filings for Apimeds Pharmaceuticals US, Inc.. This page is general information, not investment advice.